Company Filing History:
Years Active: 2017
Title: Andrew Trigwell: Innovator in Pharmaceutical Chemistry
Introduction
Andrew Trigwell is a notable inventor based in Notting Hill, Australia. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative treatments for viral infections.
Latest Patents
Andrew Trigwell holds a patent for an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole. This crystalline form is particularly useful in treating infections caused by Picornaviridae, such as the human rhinovirus (HRV). The patent also includes a method for manufacturing this free base crystalline form, which involves micronizing the compound particles, potentially using a wetting agent. Additionally, it covers pharmaceutical compositions that incorporate this crystalline form, such as tablets or suspensions, along with methods for therapeutic treatments using these compositions.
Career Highlights
Andrew Trigwell is currently associated with Aviragen Therapeutics, Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating effective pharmaceutical solutions that address pressing health concerns.
Collaborations
Andrew has collaborated with notable colleagues, including Edward Lee and David McAllister, to further enhance the impact of his innovations in the pharmaceutical industry.
Conclusion
Andrew Trigwell's contributions to pharmaceutical chemistry, particularly through his patented innovations, highlight his role as a key figure in the fight against viral infections. His work continues to pave the way for new therapeutic options in medicine.